Edison Scientific, an artificial-intelligence drug-discovery company spun out of the nonprofit FutureHouse in late 2025 with $70 million in venture funding, has been engaged by the team behind Metsera to create new biotechnology companies. The deal is an early signal that AI-agent platforms — software programs capable of reasoning and acting without step-by-step human instruction — are moving from laboratory curiosity to something that drug developers are willing to pay to have at the center of company creation.
What Edison Scientific Is and Where It Came From
FutureHouse, the nonprofit parent, was founded in 2023 by Sam Rodriques and Andrew White. Rodriques previously ran the Applied Biotechnology Lab at the Francis Crick Institute; White was a chemical engineering professor at the University of Rochester. Their original aim was broad: give every scientist access to AI agents that could reason independently and, by doing so, compress the pace of scientific discovery.
The commercial turn came unexpectedly. A top-10 drugmaker reached out to FutureHouse offering $30 million to deploy the nonprofit's AI agents for internal drug discovery. Rodriques initially assumed there had been a misunderstanding. Then a second large pharmaceutical company followed. The head of AI at that firm, as Rodriques recalled it, argued that while the company could build its own agents on top of general-purpose platforms, FutureHouse's offering was differentiated enough to make that redundant. Those inbound calls became the rationale for creating a commercial vehicle: Edison Scientific was incorporated in late 2025.
Why Pharma Is Paying Attention
The interest from established drugmakers points to a specific gap in the market. General-purpose large language models from providers such as OpenAI or Anthropic give companies a foundation, but scientific reasoning — parsing literature, forming hypotheses, designing experiments — requires agents built and evaluated for that domain. FutureHouse's position, as described by Rodriques, is that domain-specific agent design justifies a premium over commodity infrastructure.
Whether that premium holds as the underlying models improve is the central competitive question the company has not yet had to answer publicly. The $70 million in funding buys time to demonstrate results before that question becomes urgent.
The Metsera Connection
Edison Scientific's engagement by the team behind Metsera — a drug-development company in its own right — suggests the platform is now being deployed not just to support existing pipelines but to generate entirely new biotechnology entities. The structure of that arrangement, including financial terms and the number of companies targeted, has not been disclosed in available reporting. What is clear is that the thesis being tested is whether AI agents can compress the earliest, most speculative phase of drug development: the decision to start a company at all.